6/10
08:55 am
aim
AIM ImmunoTech to Participate in the Virtual Investor Pitch Conference
Low
Report
AIM ImmunoTech to Participate in the Virtual Investor Pitch Conference
6/3
09:15 am
aim
AIM ImmunoTech to Participate in the Virtual Investor Lunch Break Series
Low
Report
AIM ImmunoTech to Participate in the Virtual Investor Lunch Break Series
5/31
08:43 am
aim
AIM ImmunoTech Announces Pricing of $2.0 Million Registered Direct Offering [Yahoo! Finance]
Medium
Report
AIM ImmunoTech Announces Pricing of $2.0 Million Registered Direct Offering [Yahoo! Finance]
5/31
08:30 am
aim
AIM ImmunoTech Announces Pricing of $2.0 Million Registered Direct Offering
High
Report
AIM ImmunoTech Announces Pricing of $2.0 Million Registered Direct Offering
5/20
09:21 am
aim
AIM ImmunoTech to Participate in Two Upcoming Investor Conferences [Yahoo! Finance]
Low
Report
AIM ImmunoTech to Participate in Two Upcoming Investor Conferences [Yahoo! Finance]
5/20
09:15 am
aim
AIM ImmunoTech to Participate in Two Upcoming Investor Conferences
Low
Report
AIM ImmunoTech to Participate in Two Upcoming Investor Conferences
5/16
07:32 am
aim
AIM ImmunoTech Reports First Quarter 2024 Financial Results and Provides Corporate Update [Yahoo! Finance]
Medium
Report
AIM ImmunoTech Reports First Quarter 2024 Financial Results and Provides Corporate Update [Yahoo! Finance]
5/16
07:30 am
aim
AIM ImmunoTech Reports First Quarter 2024 Financial Results and Provides Corporate Update
Medium
Report
AIM ImmunoTech Reports First Quarter 2024 Financial Results and Provides Corporate Update
5/9
08:50 am
aim
AIM ImmunoTech to Discuss First Quarter 2024 Financial Results on May 16, 2024, and Host Conference Call and Webcast
Low
Report
AIM ImmunoTech to Discuss First Quarter 2024 Financial Results on May 16, 2024, and Host Conference Call and Webcast
5/6
08:36 am
aim
AIM ImmunoTech Completes cGMP Manufacturing of Clinical Vials of Ampligen® [Yahoo! Finance]
Medium
Report
AIM ImmunoTech Completes cGMP Manufacturing of Clinical Vials of Ampligen® [Yahoo! Finance]
5/6
08:30 am
aim
AIM ImmunoTech Completes cGMP Manufacturing of Clinical Vials of Ampligen®
Medium
Report
AIM ImmunoTech Completes cGMP Manufacturing of Clinical Vials of Ampligen®
4/29
08:55 am
aim
AIM ImmunoTech Announces First Dose Level is Generally Well-Tolerated in Phase 1b/2 Study of Ampligen and Imfinzi as a Combination Therapy for Late-Stage Pancreatic Cancer
Medium
Report
AIM ImmunoTech Announces First Dose Level is Generally Well-Tolerated in Phase 1b/2 Study of Ampligen and Imfinzi as a Combination Therapy for Late-Stage Pancreatic Cancer
4/25
08:45 am
aim
AIM ImmunoTech Announces Release of the Next CEO Corner Segment
Medium
Report
AIM ImmunoTech Announces Release of the Next CEO Corner Segment
4/18
08:45 am
aim
AIM ImmunoTech Announces Release of the Next CEO Corner Segment
Low
Report
AIM ImmunoTech Announces Release of the Next CEO Corner Segment
4/15
08:58 am
aim
AIM ImmunoTech Announces Charles Lapp, MD, as a Consulting Medical Officer for its ME/CFS and Long COVID Programs [Yahoo! Finance]
High
Report
AIM ImmunoTech Announces Charles Lapp, MD, as a Consulting Medical Officer for its ME/CFS and Long COVID Programs [Yahoo! Finance]
4/15
08:55 am
aim
AIM ImmunoTech Announces Charles Lapp, MD, as a Consulting Medical Officer for its ME/CFS and Long COVID Programs
High
Report
AIM ImmunoTech Announces Charles Lapp, MD, as a Consulting Medical Officer for its ME/CFS and Long COVID Programs
4/11
11:00 am
aim
AIM ImmunoTech Announces Release of the Next CEO Corner Segment
Medium
Report
AIM ImmunoTech Announces Release of the Next CEO Corner Segment
4/10
08:27 am
aim
AIM ImmunoTech Announces Positive Top-Line, Protocol-Planned Interim Report Data from the Study of Ampligen Combined with Pembrolizumab for the Treatment of Recurrent Ovarian Cancer [Yahoo! Finance]
Medium
Report
AIM ImmunoTech Announces Positive Top-Line, Protocol-Planned Interim Report Data from the Study of Ampligen Combined with Pembrolizumab for the Treatment of Recurrent Ovarian Cancer [Yahoo! Finance]
4/10
08:21 am
aim
AIM ImmunoTech Announces Positive Top-Line, Protocol-Planned Interim Report Data from the Study of Ampligen Combined with Pembrolizumab for the Treatment of Recurrent Ovarian Cancer
Low
Report
AIM ImmunoTech Announces Positive Top-Line, Protocol-Planned Interim Report Data from the Study of Ampligen Combined with Pembrolizumab for the Treatment of Recurrent Ovarian Cancer
4/3
09:29 am
aim
AIM ImmunoTech Inc. (AMEX:AIM) Q4 2023 Earnings Call Transcript [Yahoo! Finance]
Medium
Report
AIM ImmunoTech Inc. (AMEX:AIM) Q4 2023 Earnings Call Transcript [Yahoo! Finance]
4/2
07:39 am
aim
AIM ImmunoTech Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update [Yahoo! Finance]
High
Report
AIM ImmunoTech Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update [Yahoo! Finance]
4/2
07:30 am
aim
AIM ImmunoTech Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
High
Report
AIM ImmunoTech Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
3/28
08:17 am
aim
AIM ImmunoTech to Present at the MedInvest Biotech & Pharma Investor Conference [Yahoo! Finance]
Low
Report
AIM ImmunoTech to Present at the MedInvest Biotech & Pharma Investor Conference [Yahoo! Finance]
3/28
08:05 am
aim
AIM ImmunoTech to Present at the MedInvest Biotech & Pharma Investor Conference
Low
Report
AIM ImmunoTech to Present at the MedInvest Biotech & Pharma Investor Conference
3/26
09:18 am
aim
AIM ImmunoTech to Discuss Fourth Quarter and Full Year 2023 Financial Results on April 2, 2024, and Host Conference Call and Webcast [Yahoo! Finance]
Low
Report
AIM ImmunoTech to Discuss Fourth Quarter and Full Year 2023 Financial Results on April 2, 2024, and Host Conference Call and Webcast [Yahoo! Finance]